|
Early registration discount deadline approaching – Register by August 2 and Save up to $400!
Cambridge Healthtech Institute’s Inaugural
FAST: Functional Analysis & Screening Technologies Congress
October 28-30, 2013
Le M̩ridien Cambridge-MIT РCambridge, MA
PDF Brochure | Register | Short Courses | FASTCongress.com
Join 150+ drug R&D teams for practical discussions, solutions and case studies for refining early-stage drug discovery methods at four co-located conferences: Engineering Functional 3-D Tissue Models, Phenotypic Drug Discovery, Screening and Functional Analysis of 3-D Models, and Physiologically-Relevant Cellular Tumor Models for Drug Discovery.
Improving the screening success rate of drugs with 3-D models and phenotypic screening to eliminate ineffective and toxic compounds could save billions of dollars in R&D costs. Attend this congress and get answers to critical questions, such as:
- What 3-D model do I use to screen different cell types and measure a drug’s response?
- How do I integrate tissue engineering and systems biology in drug development?
- What are the advantages of phenotypic screening vs. target-based screening?
- How do I determine the mechanism of action (MoA) from small molecules?
- What physiologically-relevant models should be used to profile compound action and predict toxicity and efficacy?
- How are 3-D spheroid cell culture models being used in target identification of cancer?
Keynote & Featured Speakers:
Geoffrey A. Bartholomeusz, Ph.D., Assistant Professor and Director, siRNA Core Facility, Department of Experimental Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center
Karen J.L. Burg, Ph.D., Hunter Endowed Chair and Professor of Bioengineering, Clemson University
Mohanraj Dhanabal, Ph.D., Group Leader, Lead Discovery Technology, EMD Serono
Martina Fitzek, Associate Principal Scientist, Discovery Sciences, AstraZeneca
Linda Griffith, Ph.D., Professor, Biological and Mechanical Engineering and Director, Center for Gynepathology Research, Massachusetts Institute of Technology
Mitchell Ho, Ph.D., Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH
Steve Ludbrook, Ph.D., Section Head, Screening and Compound Profiling, GlaxoSmithKline
Aaron Morris, Ph.D., Lab Head, Cancer Biology, Sanofi Oncology
David C. Swinney, Ph.D., CEO, Institute for Rare and Neglected Diseases Drug Discovery (iRND3)
D. Lansing Taylor, Ph.D., Director, University of Pittsburgh Drug Discovery Institute
How to Register:
Call: 781-972-5400
Web: https://chidb.com/register/2013/fast/reg.asp
|
